Bridgewater Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Bridgewater Associates’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.27M	Sell	50,265 -91,547	-65%	-$2.01M	0.01%	801
2026 Q1	$3.16M	Buy	141,812 +3,633	+3%	+$86.8K	0.01%	537
2025 Q4	$3.69M	Sell	138,179 -25,066	-15%	-$599K	0.01%	615
2025 Q3	$3.48M	Buy	+163,245	New	+$3.86M	0.01%	577
2022 Q3	–	Sell	-10,918	Closed	-$154K	–	868
2022 Q2	$154K	Buy	10,918 +1,929	+21%	+$36K	﹤0.01%	978
2022 Q1	$218K	Buy	+8,989	New	+$218K	﹤0.01%	957

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bridgewater Associates's ACAD Position: Q2 2026 in Review

Bridgewater Associates reduced its Acadia Pharmaceuticals (ACAD) stake by 65% in Q2 2026, selling an estimated $2.01M and leaving 50,265 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #801.

Bridgewater Associates first reported a position in ACAD in Q1 2022 and has held it in 6 quarters since. The position peaked at $3.69M in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Bridgewater Associates held 50,265 shares of Acadia Pharmaceuticals worth $1.27M as of Q2 2026.
Bridgewater Associates sold 91,547 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
Acadia Pharmaceuticals made up 0.01% of Bridgewater Associates's portfolio in Q2 2026, its #801 holding.
Bridgewater Associates first reported a position in Acadia Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
Bridgewater Associates's Acadia Pharmaceuticals position peaked at $3.69M in Q4 2025.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.